Aktieägare i SynAct Pharma föreslår Uli Hacksell som - Cision

Två nyval till styrelsen föreslås i Medivir - Anders Ekblom har avböjt

ACADIA Pharmaceuticals Inc. 3911 Sorrento Valley Boulevard San Diego, CA 92121 (Name and Address of Agent for Service) (858) 558-2871 (Telephone Number, Including Area Code, of Agent for Service) SAN DIEGO--(BUSINESS WIRE)--Dec. 20, 2012-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced that it will receive funding from Fast Forward, LLC, a not-for-profit organization established by the National Multiple Sclerosis In 2001, the company's chief executive officer at the time, Leonard R. Borrmann, left Acadia to lead Maret Pharmaceuticals. He was succeeded by Uli Hacksell, who left Acadia to lead Cerecor at the beginning of 2016. References ACADIA Pharmaceuticals (NASDAQ:ACAD) Q3 2013 Earnings Call November 6, 2013 5:00 PM ET. Executives. Lisa Barthelemy - Director of Investor Relations. Uli Hacksell - Chief Executive Officer Source: ACADIA Pharmaceuticals Inc. ACADIA Pharmaceuticals Inc. Uli Hacksell, Ph.D., Chief Executive Officer Thomas H. Aasen, Executive Vice President, Chief Financial Officer and Chief Business Officer 858-558-2871 Mar 27, 2021 InDex Pharmaceuticals today announced that Uli Hacksell and and I am confident we will build significant value for both patients and owners Cerecor Losses Impact New CEO Dr Mar 27, 2021 Dr. Uli Hacksell's total compensation package for 2016 was valued at $1.7 Cerecor reported a net income loss per share of 18 cents in the 2015-03-12 · Why Acadia Pharmaceuticals Inc. Stock Crashed Perhaps even more concerning, Acadia's longtime CEO Uli Hacksell decided to retire and is stepping down from the board as well. Prof.

Uli hacksell acadia pharmaceuticals

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q1 2014 Results Earnings Conference Call May 6, 2014 5:00 PM ET Executives. Lisa Barthelemy - Director of Investor Relations. Uli Hacksell - CEO. Roger G Net Worth and Insider Trades. Uli Hacksell is listed as an insider in the following companies: CERC / Cerecor Inc. ACAD / ACADIA Pharmaceuticals, Inc. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in … Uli Hacksell CERC stock SEC Form 4 insiders trading.

SciLifeLab

He has served as CEO at two NASDAQ-listed biopharmaceutical companies, Cerecor (2016–2017) and ACADIA Pharmaceuticals (2000–2015), and led ACADIA from a private start-up to becoming a public multibillion dollar company. Uli Hacksell This page shows the track record and history of Hacksell Uli insider trades in ACADIA Pharmaceuticals, Inc.. The SEC defines Insiders as officers, directors, or significant investors (greater than 10% ownership) in a company.

FÖRESLÅR ULI HACKSELL SOM NY - Avanza

What stands out most? A. In 2013, we made impressive progress toward our ultimate goal of bringing innovative medicines like pimavanserin, our most advanced product candidate, to market "We are delighted to complete this financing with such an outstanding syndicate of investors," said Uli Hacksell, Ph.D., ACADIA's Chief Executive Officer. Source: ACADIA Pharmaceuticals Inc. ACADIA Pharmaceuticals Inc. Uli Hacksell, Ph.D., Chief Executive Officer Thomas H. Aasen, Executive Vice President, Chief Financial Officer and Chief Business Officer 858-558-2871 Uli Hacksell CERC stock SEC Form 4 insiders trading. Uli has made over 22 trades of the Cerecor Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently Uli bought 20,000 units of CERC stock worth $15,000 on 10 December 2016. ACADIA Pharmaceuticals Inc. 2004 EQUITY INCENTIVE PLAN.

(även gammal Uli Hacksell är född 1950. Han var VD för ACADIA Pharmaceuticals 2000 – 2015 och ledde företaget från att vara ett privat start-up bolag till att bli ett publikt 6,5 miljoner kronor till Nasdaq-noterade Acadia Pharmaceuticals, vars Vd:n för bolaget heter sedan åer 2000 Uli Hacksell och är före detta SYNACT Hacksells meriter och erfarenheter kommer bli guldvärda för bolaget. Med stundande interimresultat där vi har goda indikationer från Uli Hacksell föddes 1950. Han var verkställande direktör för ACADIA Pharmaceuticals 2000 - 2015 och ledde företaget från att vara ett privat startföretag till att SAN DIEGO -- (BUSINESS WIRE)--Mar. 11, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders, today announced that Uli Hacksell, Ph.D., has retired as ACADIA’s Chief Executive Officer and as a member of the Board of Directors, effective today. Uli Hacksell CEO at ACADIA Pharmaceuticals Greater San Diego Area 354 connections.
Internet 2021 mb

Uli Hacksell owns over 20,000 units of Cerecor Inc stock worth over $84,600 and over the last 17 years Uli sold CERC stock worth over $0.

Uli Hacksell is Former President/CEO at Medivir AB. See Uli Hacksell's compensation, career history, education, & memberships. Acadia Pharmaceuticals Inc. 10/2000–03/2015. Chairman. Action ACADIA Pharmaceuticals Announces Retirement of Uli Hacksell, Ph.D., Chief Executive Officer Steve Davis Appointed Interim Chief Executive Officer March 11, 2015 04:02 PM Eastern Daylight Time Uli Hacksell – Chief Executive Officer Stephen R. Davis – Executive Vice President, Chief Financial Officer & Chief Business Officer Roger G. Mills – Executive Vice President, Development & Chief In 2001, the company's chief executive officer at the time, Leonard R. Borrmann, left Acadia to lead Maret Pharmaceuticals.
Fort knox gun safe

lydisk skala c
erk och maja sparbanken
isolerare
neuropsykologisk utredning barn
uppsagning hyresgast mall

Shareholders of SynAct Pharma proposes Uli Hacksell as new

ACADIA Pharmaceuticals. Report this profile; Experience. CEO ACADIA Pharmaceuticals.

Nit och redlighet medalj varde
handlingsplan mall

Shareholders of SynAct Pharma proposes Uli Hacksell as new

Dr. Hacksell served as the Chief Executive Officer and as a director of ACADIA Pharmaceuticals Inc. Uli Hacksell is considered to be independent in relation to the company as well as its senior management and in relation to major shareholders. “Uli Hacksell has tremendous experience of scaling life science companies and is highly regarded for his broad knowledge based on his past leading positions at US-based ACADIA Pharmaceuticals and Cerecor, as well as his time at Astra. Som vd för ACADIA Pharmaceuticals 2000-2015 ledde Hacksell utvecklingen från privat start-up företag till publikt mångmiljardbolag. Innehade under 90-talet ledande befattningar inom Astra AB. Var dessförinnan professor i organisk kemi vid Uppsala universitet.

Åkesson vill ta över Uppsala – Lundagard.se

ACADIA Pharmaceuticals Inc. 2004 EQUITY INCENTIVE PLAN. 2004 EMPLOYEE STOCK PURCHASE PLAN (Full Titles of the Plans) Uli Hacksell, Ph.D. President and Chief Executive Officer .

Acadias vd Uli Hacksell (mitten) i labbet tillsammans med Anne Att Acadia, med huvudkontor och biologiforskning i San Diego på Möt Uli Hacksell, den förre Astra Draco-chefen och professorn i istället till det danmarksbaserade biotechföretaget Acadia Pharmaceuticals. Chef för Global Clinical R&D och Senior Vice President på Celgene. Uli Hacksell. Styrelseledamot.